Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $155.60 Consensus Price Target from Analysts

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have received an average rating of “Buy” from the seventeen research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $155.60.

Several analysts have recently commented on the stock. Stifel Nicolaus increased their price target on shares of Palvella Therapeutics from $87.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, November 24th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $193.00 target price on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. UBS Group reiterated a “buy” rating and set a $143.00 target price on shares of Palvella Therapeutics in a report on Monday, December 15th. Craig Hallum began coverage on Palvella Therapeutics in a report on Thursday, December 4th. They issued a “buy” rating and a $175.00 price target for the company. Finally, HC Wainwright set a $200.00 price objective on Palvella Therapeutics and gave the company a “buy” rating in a research report on Monday, December 15th.

Palvella Therapeutics Stock Down 2.3%

NASDAQ PVLA opened at $103.37 on Thursday. Palvella Therapeutics has a 52 week low of $11.17 and a 52 week high of $114.69. The firm has a 50 day moving average of $88.84 and a two-hundred day moving average of $60.19. The stock has a market capitalization of $1.22 billion, a PE ratio of -39.30 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). On average, equities research analysts expect that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $96.47, for a total value of $415,013.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

Large investors have recently added to or reduced their stakes in the business. Archer Investment Corp purchased a new stake in Palvella Therapeutics in the 3rd quarter valued at about $28,000. Russell Investments Group Ltd. acquired a new stake in shares of Palvella Therapeutics in the third quarter worth approximately $36,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Palvella Therapeutics in the second quarter worth approximately $37,000. JPMorgan Chase & Co. grew its holdings in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Palvella Therapeutics during the second quarter worth approximately $85,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.